Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database

• DOI: 10.3389/fphar.2022.803706
• Publication Date: 2022-03-29T19:07:40Z
• Authors: Koki Kato; Tomohiro Mizuno; Takenao Koseki; Yoshimasa Ito; Kazuo Takahashi; Naotake Tsuboi; Shigeki Yamada
• Keywords: Polymyalgia rheumatica

Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we examined the frequency of by analyzing data recorded in Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, as an immune-related adverse event was defined according 2012 revised International Chapel Hill Consensus Conference Nomenclature Vasculitides. signals recognized significant when reporting odds ratio estimates lower limits corresponding 95% confidence intervals exceeded 1. The use nivolumab showed a signal vasculitides. Furthermore, polymyalgia rheumatica found patients treated with nivolumab, pembrolizumab, ipilimumab. In addition, frequencies nivolumab- pembrolizumab-induced higher aged ≥70 years female patients, respectively. Polymyalgia reported 38 nivolumab; 31 (82%) these either recovery or remission. Further, 17 pembrolizumab; 13 (76%) remission, while three (18%) not. 12 ipilimumab; seven (58%) Our study highlights that careful monitoring symptom PMR (e.g., bilateral pain shoulder pelvic girdles) required are >70 women pembrolizumab.